Surveillance Recommendations in Reducing Risk of and Optimally Managing Breast Cancer-Related Lymphedema
AbstractBreast cancer survivors are at increased risk for the development of breast cancer-related lymphedema (BCRL), a chronic, debilitating, and disfiguring condition that is progressive and requires lifelong self-management of symptoms. It has been reported that over 40% of the 2.5 million breast cancer survivors in the United States may meet the criteria for BCRL during their lifetimes. Ongoing surveillance, beginning with pre-operative assessment, has been effective in identifying subclinical lymphedema (LE). A prospective model for surveillance is necessary in order to detect BCRL at an early stage when there is the best chance to reduce risk or slow progression. Physical methods for monitoring and assessment, such as circumferential arm measures, perometry, bioimpedance; exercise programs; prophylactic and early-intervention compression garments; and referral for complete decongestive therapy are all interventions to consider in the development of a BCRL surveillance program. In addition, supportive-educative programs and interactive engagement for symptom self-management should also be implemented. The importance of interdisciplinary collaboration is integral to the success of an effective personalized medicine program in breast cancer-related lymphedema surveillance. View Full-Text
Share & Cite This Article
Ostby, P.L.; Armer, J.M.; Dale, P.S.; Van Loo, M.J.; Wilbanks, C.L.; Stewart, B.R. Surveillance Recommendations in Reducing Risk of and Optimally Managing Breast Cancer-Related Lymphedema. J. Pers. Med. 2014, 4, 424-447.
Ostby PL, Armer JM, Dale PS, Van Loo MJ, Wilbanks CL, Stewart BR. Surveillance Recommendations in Reducing Risk of and Optimally Managing Breast Cancer-Related Lymphedema. Journal of Personalized Medicine. 2014; 4(3):424-447.Chicago/Turabian Style
Ostby, Pamela L.; Armer, Jane M.; Dale, Paul S.; Van Loo, Margaret J.; Wilbanks, Cassie L.; Stewart, Bob R. 2014. "Surveillance Recommendations in Reducing Risk of and Optimally Managing Breast Cancer-Related Lymphedema." J. Pers. Med. 4, no. 3: 424-447.